ClinicalTrials.gg
Not yet recruitingNCT07271706Updated Dec 9, 2025

The Effect of Laughter Yoga in Type 2 Diabetes Patients

An interventional study of Laughter yoga in Diabetic, Laughter Yoga and Comfort, sponsored by Bozok University. Not yet recruiting. Open to participants aged 18 Months and older. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by Bozok University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Months and older
Sex
All
01

Study summary

The purpose of this study is to examine the effect of laughter yoga on self-management skills and comfort levels in patients with Type 2 diabetes.

Read the detailed description

Diabetes is a major global health problem affecting more than 537 million adults worldwide, a number expected to rise substantially in the coming decades. Type 2 diabetes, the most prevalent form, requires consistent self-management to maintain glycemic control and prevent complications. However, individuals living with chronic illness often experience ongoing physiological fatigue and emotional stress, which can reduce self-efficacy and hinder engagement in self-management behaviors. Comfort, identified as an important psychological resource, plays a supportive role in sustaining these behaviors.

Katharine Kolcaba's Comfort Theory proposes that health behaviors can be positively influenced by enhancing individuals' physical, psychospiritual, sociocultural, and environmental comfort. Laughter Yoga-a mind-body intervention combining intentional laughter with breathing and relaxation techniques-has been shown to reduce stress, improve mood, and increase parasympathetic activity. Previous studies involving individuals with Type 2 diabetes have reported reductions in HbA1c, decreased stress levels, and improved quality of life following Laughter Yoga interventions. However, limited research has simultaneously examined its effects on both self-management behaviors and comfort levels.

This study aims to evaluate the effects of Laughter Yoga on self-management behaviors and comfort levels among individuals with Type 2 diabetes.

02

Conditions studied

  • Diabetic
  • Laughter Yoga
  • Comfort

Keywords

  • laughter yoga
  • diabetic
  • comfort
  • self-governance
03

In context

Lead sponsor

Bozok University is the lead sponsor of 54 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Type 2 diabetes
  • Age 18 years or older
  • Willingness to participate in the Laughter Yoga intervention
  • Ability to read and comprehend Turkish

Exclusion criteria

Exclusion Criteria

  • Diagnosis of Type 1 diabetes
  • Participation in individual psychotherapy or group-based psychological intervention programs
  • Experience of a recent loss within the past month (e.g., death, divorce)
  • Presence of any psychiatric diagnosis
  • Use of psychiatric medication
  • Severe visual or hearing impairment preventing active participation in the intervention
  • Pregnancy or breastfeeding
  • Limitations in reading or comprehending Turkish
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
80 participants (estimated)

Study arms

  • No intervention
    control group
  • Experimental
    Laughter yoga

    Behavioral: Laughter yoga

Interventions

  • BehavioralLaughter yoga

    Arm Description: A structured laughter yoga program delivered twice weekly for four weeks. Each 40-minute session includes warm-up and breathing exercises (5-7 min), guided laughter exercises (15-20 min), diaphragmatic breathing and relaxation (5-7 min), and mindfulness-based closing practices (3-5 min). Conducted by a certified facilitator.

06

What researchers measure

Primary outcomes

  1. Diabetes Self-Management Score (Diabetes Self-Management Questionnaire - DSMQ)

    The Diabetes Self-Management Questionnaire (DSMQ), originally developed by Schmitt et al. (2013), will be used to evaluate diabetes self-management behaviors. The DSMQ consists of 16 items and four subscales: Glucose Management Dietary Control Physical Activity Health-Care Use Items are rated on a 4-point Likert scale (0-3). Seven items are scored positively, and nine items are reverse-scored. Total scores are calculated by dividing the raw score by the maximum possible score and multiplying by 10. The resulting values range from 0 to 10, with higher scores indicating better diabetes self-management.

    Time frame: Baseline (Day 0) and Week 4

  2. Comfort Level Score (General Comfort Questionnaire - Short Form)

    The General Comfort Questionnaire - Short Form, developed by Kolcaba (2006), will be used to assess comfort levels across physical, psychospiritual, environmental, and social domains. The scale consists of 28 items and three subscales: Relief Ease Transcendence Items are rated on a 6-point Likert scale (1-6). Negative items are reverse-scored. The total comfort score ranges from 1 to 6, with higher scores indicating greater comfort.

    Time frame: Baseline (Day 0) and Week 4

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Dec 2025, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 9, 2025
StartEst.
Dec 15, 2025
Primary completionEst.
Dec 25, 2025
CompletionEst.
Jan 25, 2026
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07271706
Lead sponsor
Bozok University
Responsible party
Betül Bal (Lecturer Doctor, Bozok University) — Principal investigator
First posted
Dec 9, 2025
Start date
Dec 15, 2025 (estimated)
Primary completion
Dec 25, 2025 (estimated)
Completion
Jan 25, 2026 (estimated)
Last update
Dec 9, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion